---
schema_version: "secwatch.filing_event.v1"
accession: "0001125345-23-000058"
form_type: "8-K"
ticker: "MGNX"
cik: "0001125345"
company_name: "MACROGENICS INC"
filed_at: "2023-03-15T23:59:59+00:00"
generated_at: "2026-06-18T01:40:28.685236+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MacroGenics reports 2022 net loss of $119.8M; cash runway extended through 2025 via $250M non-dilutive funding

## Summary
- Net loss $119.8M ($1.95/share) vs $202.1M in 2021; revenue $151.9M (up 96% YoY).
- Cash $154.3M at Dec 2022; plus $100M from DRI royalty sale; runway through 2025.
- TAMARACK trial modified: removed control arm; clinical update expected in 2024.
- Lorigerlimab mCRPC data: 28.6% PSA50, 25.7% confirmed partial responses.
- TZIELD approval milestone: two $15M payments received; two due by Sept 2023.

## SEC filing metadata
- accession: 0001125345-23-000058
- form_type: 8-K
- ticker: MGNX
- cik: 0001125345
- company_name: MACROGENICS INC
- filed_at: 2023-03-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1125345/000112534523000058/0001125345-23-000058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1125345/000112534523000058/mgnx-20230315.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001125345-23-000058
- JSON: https://secwatch.observer/filing/0001125345-23-000058.json
- Plain text: https://secwatch.observer/filing/0001125345-23-000058.txt

## Key facts
- Earnings Releases
  MACROGENICS INC reported financial results for the year ended December 31, 2022.
  - Period: the year ended December 31, 2022
  - Result: reported results
  source text: On March 15, 2023, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1125345/000112534523000058/0001125345-23-000058-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.